• PLAC1 as a Prognostic Biomarker and Target in ccRCC: New Ins

  2026-05-13

  The referenced study identifies PLAC1 as a prognostic biomarker and actionable molecular target in clear cell renal cell carcinoma (ccRCC), demonstrating its high expression correlates with poor prognosis. Using high-throughput virtual screening, the authors discovered small-molecule inhibitors that suppress PLAC1, suggesting novel therapeutic opportunities for ccRCC and informing precision anti-cancer drug discovery.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-13

  This study identifies IGF2BP3 as a dominant m6A reader that stabilizes FZD1/7 transcripts, activating β-catenin signaling and enhancing stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC). Disrupting the IGF2BP3–FZD1/7 axis sensitizes cancer stem cells to chemotherapy, offering a new therapeutic target.

• KR-12 Human Antimicrobial Peptide: Protocols and Biofilm Sol

  2026-05-12

  KR-12, the minimal human antimicrobial peptide, delivers targeted anti-biofilm and immunomodulatory action with minimal cytotoxicity, setting it apart from broader-spectrum AMPs. This practical guide synthesizes validated workflows, troubleshooting, and data-backed insights to help researchers maximize the translational impact of KR-12 (human) TFA in infection and inflammation models.

• High-Throughput Screening of HIV-1 Protease Autoprocessing I

  2026-05-12

  This study presents a validated cell-based AlphaLISA assay for high-throughput screening of compounds that inhibit HIV-1 protease autoprocessing, a crucial step in viral maturation and drug resistance. The platform demonstrates both specificity for known protease inhibitors and utility in assessing resistance mutations, informing future antiviral drug discovery.

• AZ505, a Potent and Selective SMYD2 Inhibitor: Lab Scenarios

  2026-05-11

  This article delivers authoritative, scenario-driven guidance on using AZ505, a potent and selective SMYD2 inhibitor (SKU B1255), to address core challenges in epigenetic regulation research, cancer biology, and renal fibrosis models. By integrating validated protocols and peer-reviewed data, biomedical scientists and lab technicians gain practical strategies to optimize assay reproducibility and interpretability with AZ505.

• AZ505 SMYD2 Inhibitor: Protocols and Insights for Epigenetic

  2026-05-11

  AZ505, a potent and selective SMYD2 inhibitor, empowers researchers to interrogate histone and non-histone methylation in disease-relevant cellular models. This guide translates cutting-edge findings into actionable protocols and troubleshooting strategies for cancer biology and fibrosis research.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Protocols & Resea

  2026-05-10

  Digoxin stands out as a high-purity Na+/K+ ATPase pump inhibitor, enabling both advanced cardiac contractility research and targeted chikungunya virus inhibition studies. This article details applied workflows, troubleshooting strategies, and how APExBIO’s Digoxin supports robust, reproducible data across diverse cell and animal models.

• Chlorpromazine Hydrochloride: Advanced Workflows in Antipsyc

  2026-05-09

  Chlorpromazine hydrochloride from APExBIO unlocks reproducible, high-precision dopamine receptor research and sophisticated CNS disease models. Leveraging new insights into hepatic nanoparticle interactions, this guide details protocol enhancements and troubleshooting strategies for maximizing experimental accuracy and translational relevance.

• Innovating RNA Probe Design: Mechanistic & Strategic Insight

  2026-05-08

  This thought-leadership article explores how mechanistic understanding of RNA labeling, exemplified by APExBIO’s HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit, empowers translational researchers to address complex gene regulation and detection challenges. By integrating evidence from recent sepsis biomarker studies and advanced labeling workflows, we chart a course for robust, reproducible, and clinically relevant RNA probe development.

• Cytoskeleton-Dependent Autophagy Under Mechanical Stress: Ne

  2026-05-08

  Liu et al. (2024) provide the first direct evidence that the cytoskeleton—particularly microfilaments—plays an essential and distinct role in mechanical stress-induced autophagy in human cell lines. These findings clarify how mechanical signals are transduced to regulate autophagic responses, informing both fundamental cell biology and the design of mechanotransduction-targeted assays.

• DiscoveryProbe Protease Inhibitor Library: Applied HTS Insig

  2026-05-07

  The DiscoveryProbe™ Protease Inhibitor Library empowers high-throughput and high-content screening with 825 validated, cell-permeable compounds spanning all major protease classes. This article translates experimental workflows and troubleshooting strategies into actionable steps for apoptosis, cancer, and infectious disease research, highlighting unique advantages of APExBIO's assay-ready platform.

• Differential Volatile Profiles of Chuanxiong Cortex and Pith

  2026-05-07

  This study employs advanced SPME-GC×GC-MS and network pharmacology to distinguish the volatile metabolite and target profiles of cortex versus pith tissues from Ligusticum chuanxiong in coronary heart disease (CHD) prevention. The findings reveal tissue-specific bioactive components—such as Fenipentol—offering new mechanistic insights and rationales for precision herbal medicine.

• Pentoxifylline Enhances Sperm Motility in Assisted Reproduct

  2026-05-06

  This review analyzes the mechanistic and practical evidence for in vitro pentoxifylline use to improve sperm function in assisted male reproduction. It synthesizes protocol details, efficacy outcomes, and limitations, providing actionable insights for ART researchers.

• Targeting DHHC9-Mediated Palmitoylation to Limit YAP-Driven

  2026-05-06

  This study uncovers DHHC9-mediated palmitoylation of STRN4 as a critical driver of YAP-dependent cancer metastasis. Through genetic and pharmacological inhibition, the research demonstrates that targeting this pathway effectively suppresses metastatic behaviors, highlighting DHHC9 as a promising therapeutic target for adenocarcinoma.

• Poly-GA Drives Tau Pathology via ERK1/2: U0126 Reveals Mecha

  2026-05-05

  This study identifies poly-glycine-alanine (poly-GA) as a direct activator of ERK1/2, amplifying tau phosphorylation and aggregation in C9orf72-linked frontotemporal lobar degeneration (FTLD). Pharmacological inhibition of ERK1/2 using U0126 robustly attenuates tau pathology and cell death, delineating a mechanistic link and highlighting potential therapeutic strategies.

15208 records 1/1014 page Next 12345 下5页 Last page